Loading stock data…
Caris Life Sciences (CAI)
$24.82-0.25 (-1.00%)
Market ClosedLast close Sep 8
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Caris Life Sciences, Inc. in the Healthcare sector is trading at $24.82 with a market capitalization of $5.2B. Wall Street consensus targets $27.50 (12 analysts), implying a +10.8% move over the next 12 months. The stock is currently 29% below its 52-week high of $35.20, remaining 18.5% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +10.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $216.17M↓ | $292.89M↑ | $216.83M↑ | $181.40M↑ | $120.92M |
| Gross Profit | $141.35M↓ | $220.91M↑ | $147.51M↑ | $113.69M↑ | $57.06M |
| Operating Income | $5.28M↓ | $88.41M↑ | $32.64M↑ | -$17.99M↑ | -$57.95M |
| Net Income | -$510,000↓ | $81.96M↑ | $24.32M↑ | -$71.79M↑ | -$102.58M |
Peer Comparison
JNJUNHPFE
Fundamentals
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.15B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.73%
Volume
Today's trading volume
4.58M
Recent News
Could Caris Life Sciences (CAI) Be 7% Undervalued After Its Lung Cancer Research Update?
Caris Life Sciences (CAI) is drawing fresh attention after announcing that its researchers will present seven lung cancer studies at the 2026 World Conference on Lung Cancer in Seoul this month. For investors, the World Conference presentations and August’s pancreatic cancer AI publication land against a mixed share price backdrop for Caris Life Sciences, with the stock down 28.06% on a 1 year total shareholder return basis but showing strong 90 day share price momentum of 55.33% and a 30 day...
Caris Life Sciences (CAI) Will Present Seven Studies At A Global Lung Conference
Caris Life Sciences (NasdaqGS: CAI) announced plans to present seven major precision oncology studies at the IASLC 2026 World Conference on Lung Cancer. The company highlighted new data on molecular profiling and AI powered analysis for lung cancer care. Caris also published a validated AI driven method designed to help optimize first line pancreatic cancer treatment choices. For readers following how AI is reshaping cancer research and treatment, it can also be useful to look at other...
What’s Next For Caris Life Sciences (CAI) After 21% Jump?
After soaring by as much as 21.58 percent on Thursday, Caris Life Sciences Inc. (NASDAQ:CAI) heads into the next trading session with investors focused less on a stellar earnings performance and more on whether it can sustain its momentum towards a recovery. To recall, the company reported strong earnings results in the second quarter of […]
Why BillionToOne Plummeted 38%, Leading A Medtech Sell-Off
Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise.
Caris Life Sciences, Inc. Q2 2026 Earnings Call Summary
Moby summary of Caris Life Sciences, Inc.'s Q2 2026 earnings call